

INFORMATION AND DISCLOSURE STATEMENT

Pursuant to Rule 15c2-(11)(a)(5) under the Securities Exchange Act of 1934

Period Ending
March 31, 2014



Medical Marijuana, Inc.

**4901 Morena Blvd, Suite 701
San Diego, CA 92117**

**CUSIP: 58463A105
Trading Symbol: MJNA**

**INFORMATION AND DISCLOSURE STATEMENT PURSUANT TO
RULE 15c2-(11)(a)(5)**

All information contained in this Information and Disclosure Statement has been compiled to fulfill the disclosure requirements of Rule 15c211 (a)(5) promulgated under the Securities Exchange Act of 1934, as amended. The enumerated captions contained herein correspond to the sequential format as set forth in the rule.

FORWARD LOOKING STATEMENTS

This Quarterly Report contains forward-looking statements. To the extent that any statements made in this report contain information that is not historical, these statements are essentially forward-looking. Forward-looking statements can be identified by the use of words such as “expects”, “plans”, “may,” “anticipates”, “believes”, “should”, “intends”, “estimates”, and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, marketability of our products; legal and regulatory risks associated with the share exchange our ability to raise additional capital to finance our activities; the effectiveness, profitability and; the future trading of our common stock; our ability to operate as a public company; our ability to protect our proprietary information; general economic and business conditions; the volatility of our operating results and financial condition; our ability to attract or retain qualified senior management personnel and research and development staff; and other risks detailed from time to time in our filings with the OTC Markets (the “OTC”), or otherwise.

Information regarding market and industry statistics contained in this report is included based on information available to us that we believe is accurate. It is generally based on industry and other publications that are not produced for purposes of securities offerings or economic analysis. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services. We do not undertake any obligation to publicly update any forward-looking statements. As a result, investors should not place undue reliance on these forward-looking statements.

FOOD AND DRUG ADMINISTRATION DISCLOSURE (FDA)

The statements found herein have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent any disease or medical condition.

1. NAME OF ISSUER AND ITS PREDECESSORS (IF ANY)

Medical Marijuana, Inc. (the “Company”, “we”, “our”, “us”, “MJNA”) was originally incorporated as Berkshire Collection, Inc., in Canada in 2003. Subsequently, we changed our domicile to Oregon and changed our name on two separate occasions. On April 28, 2009, we changed our name Medical Marijuana, Inc. and trading symbol to “MJNA.”

2. ADDRESS OF ISSUER PRINCIPAL EXECUTIVE OFFICES

Company Headquarters:

Address: 4901 Morena Boulevard, Suite 701, San Diego, CA 92117
Phone: (866) 273-8502
Email: info@medicalmarijuanainc.com
Website: www.medicalmarijuanainc.com

Investors Relations Contact:

SmallCapVoice.Com, Inc. - Stuart Smith
Phone: (512) 267-2430
Email: ssmith@smallcapvoice.com
Website: www.smallcapvoice.com

Internal - Investor Relations Contact

Perry Coleman
Phone: (443) 453-5088
perry@medicalmarijuanainc.com

3. SECURITY INFORMATION

Trading Symbol: MJNA

Exact title and class of securities outstanding: Common Stock

CUSIP: 58463A105

Par or Stated Value: \$.001 per share of Common Stock

Total shares authorized: 5,000,000,000

Total shares currently capped by management: Since the appointment of current management in March of 2011, we have internally capped the issuable common shares of the Company at

950,000,000 (as of 03/31/14)

Total shares outstanding: 949,040,104 (as of 03/31/14)

Transfer Agent:

First American Stock Transfer, Inc.

4747 N. 7th Street, Suite 170

Phoenix, AZ 85014

(602) 485-1346; (602) 788-0423 fax

<https://firstamericanstock.com>

First American Stock Transfer, Inc. is registered under the Exchange Act with the Securities Exchange Commission as a Registrar and Transfer Agent.

Is the Transfer Agent registered under the Exchange Act? Yes

Describe any trading suspension orders issued by the SEC in the past 12 months:

NONE.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the last 12 months:

NONE.

4. ISSUANCE HISTORY

As of March 31, 2014:

Shares Issued: NONE

Shares Voided: 100,000

5. FINANCIAL STATEMENTS

- A. Audit Letter;
- B. Balance sheet;
- C. Statement of income;
- D. Statement of cash flows;
- E. Financial notes.

Independent Accountant's Review Report

Board of Directors

Medical Marijuana, Inc.

San Diego, California

I have reviewed the accompanying balance sheet of Medical Marijuana, Inc. as of March 31, 2014, and the related statements of income, and cash flows for the period of January 1, 2014 through March 31, 2014. A review includes primarily applying analytical procedures to management's financial data and making inquiries of company management. A review is substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the financial statements as a whole. Accordingly, I do not express such an opinion.

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for designing, implementing, and maintaining internal control relevant to the preparation and fair presentation of the financial statements.

My responsibility is to conduct the review in accordance with Statements on Standards for Accounting and Review Services issued by the American Institute of Certified Public Accountants. Those standards require us to perform procedures to obtain limited assurance that there are no material modifications that should be made to the financial statements. I believe that the results of my procedures provide a reasonable basis for my report.

Based on my review, I am not aware of any material modifications that should be made to the accompanying financial statements in order for them to be in conformity with accounting principles generally accepted in the United States of America.

Anthony W. Imbimbo, CPA

May 10, 2014

Medical Marijuana, Inc.
Balance Sheet
As of March 31, 2014

	TOTAL
ASSETS	
Current Assets	
Checking/Savings	\$ 2,730,064
Total Accounts Receivable	1,073,845
Other Current Assets	
Inventory Asset	3,290,942
Merchant Account Reserves	61,029
Note Receivables	
Note Receivable RSI	124,500
Receivable RDH	2,977,632
Oil Sales Receivable	6,231
RSHO	5,015
Phytosphere Receivable	103,029
Note Receivables - Other	1,471,517
Total Note Receivables	4,687,923
Total Prepaid Assets	268,380
Security Deposit	4,686
Investments in Marketable Securities	30,417,671
Total Other Current Assets	38,730,632
Total Current Assets	42,534,541
Fixed Assets net of Accumulated Depreciation	1,405,380
Other Assets	
Business Investments	
Extract Dev, Marketing	3,524,085
HempVAP	4,726
Business Investment - Other	1,450,000
HempMeds PX	271,099
Kannalife	500,000
Red Dice Holdings	1,450,000
CanChew Biotech	6,559,279
Total Business Investments	13,759,189
Total Other Assets	13,759,189
TOTAL ASSETS	\$ 57,699,110

The accompanying notes are an integral part of these financial statements

Medical Marijuana, Inc.
Balance Sheet
As of March 31, 2014

	TOTAL
LIABILITIES & EQUITY	
Liabilities	
Current Liabilities	
Accounts Payable	\$ 3,840,217
Credit Cards Payable	121,489
Other Current Liabilities	
Note Payables	
Note Payable HDDC	4,359,183
Note Payable HempMeds	25,000
Note Payable HempVAP	153,575
Note Payable Kannaway	479,987
Note Payable MJNA	329,729
Note Payable MPSI	(121,505)
Note Payable HDDC Hold	35,000
Note Payable Red Dice Holdings	(36,477)
Note Payable HempMedsPX	7,631
Note Payables - Other	1,652,241
Total Note Payables	6,884,364
Payroll Liabilities	77,867
Accrued Sales Tax Payable	31,121
Process Holding Account	12,791
Total Other Current Liabilities	7,006,144
Total Current Liabilities	10,967,850
Total Liabilities	10,967,850
Equity	
Capital Stock	2,416,667
Dividends Paid	(201,500)
Less Net Income from Non Ownership Portion of Subsidiaries	45,807
Opening Balance Equity	242
Retained Earnings	31,982,956
Net Income	23,735
Common Stock	948,508
Additional Paid in Capital	11,514,846
Total Equity	46,731,261
TOTAL LIABILITIES & EQUITY	\$ 57,699,111

The accompanying notes are an integral part of these financial statements

Medical Marijuana Inc.
Statement of Income
January 1, 2014 through March 31, 2014

	TOTAL
Ordinary Income/Expense	
Sales	\$ 4,017,774
Cost of Goods Sold	\$ 1,901,747
Gross Profit	\$ 2,116,027
General and Administrative Expenses	
Advertising, Marketing and Promotion	383,854
Automobile Expense	4,860
Bank and Merchant Service Charges	199,253
Computer and Internet Expenses	170,113
Contributions	4,536
Depreciation Expense	14,528
Dues and Subscriptions	13,097
Insurance Expense	20,782
Meals and Entertainment	12,328
Office Expense	65,415
Rent Expense	68,795
Repairs and Maintenance	2,545
Security	12,320
Postage and Shipping Expense	100,691
Taxes and Licenses	5,623
Telephone Expense	7,744
Travel Expense	159,450
Utilities	5,954
Payroll and Benefits	456,617
Professional Services	350,963
Total General and Administrative Expense	2,059,465
Net Ordinary Income	\$ 56,562
Other Income or Expense	12,980
Less Net Income from Non Ownership Portion of Subsidiaries	45,807
Net Other Income	(32,827)
Net Income	\$ 23,735

The accompanying notes are an integral part of these financial statements

Medical Marijuana Inc.
Statement Of Cash Flow
January through March 2014

	TOTAL
OPERATING ACTIVITIES	
Net Income	\$ 23,735
Adjustments to reconcile Net Income to net cash provided by operations:	
Accounts Receivable	(917,251)
Inventory Asset	(2,413,033)
Note Receivables	(1,330,915)
Prepaid Assets	(250,805)
Security Deposit	(2,373)
Accounts Payable	2,308,030
Note Payables	4,441,640
Payroll Liabilities	76,493
Sales Tax	2,210
American Express	121,489
Process Holding Account	12,791
Net cash provided by Operating Activities	2,072,012
INVESTING ACTIVITIES	
Fixed Assets Net of Accumulated Depreciation	(102,226)
Net cash provided by Investing Activities	(102,226)
FINANCING ACTIVITIES	
Non Owned Equity	(127,917)
Net cash provided by Financing Activities	(127,917)
 Net cash increase for period	 1,841,869
 Cash at beginning of period	 888,195
Cash at end of period	<u><u>\$ 2,730,064</u></u>

The accompanying notes are an integral part of these financial statements

Medical Marijuana Inc.
Consolidating Statement of Income
January 1, 2014 through March 31, 2014

	Red Dice Holdings	CanChew Bio- Technologies, LLC	Hemp Vap	HempMedsPX	HempWire LLC	Medical Marijuana, Inc.	MJNA Holdings	Wellness Managed Services	TOTAL
Ordinary Income/Expense									
Sales	\$ 417,264	\$ 47,730	\$ 261,346	\$ 3,063,435	\$ -	\$ -	\$ 189,507	\$ 38,493	\$ 4,017,774
Cost of Goods Sold	\$ 186,400	\$ 4,846	\$ 153,194	\$ 1,548,725	\$ -	\$ -	\$ -	\$ 8,582	\$ 1,901,747
Gross Profit	\$ 230,864	\$ 42,884	\$ 108,152	\$ 1,514,710	\$ -	\$ -	\$ 189,507	\$ 29,911	\$ 2,116,027
General and Administrative Expenses									
Advertising, Marketing and Promotion	12,017	4,295	2,313	360,048	-	529	-	4,652	383,854
Automobile Expense	1,056	-	-	-	-	1,031	-	2,773	4,860
Bank and Merchant Service Charges	10,981	255	50	96,758	-	460	90,371	378	199,253
Computer and Internet Expenses	-	-	-	163,357	-	6,156	-	600	170,113
Contributions	241	-	-	4,295	-	-	-	-	4,536
Depreciation Expense	7,290	-	-	7,238	-	-	-	-	14,528
Dues and Subscriptions	2,500	-	-	8,670	-	-	-	1,927	13,097
Insurance Expense	1,642	-	-	16,458	-	1,745	-	936	20,782
Meals and Entertainment	1,212	-	-	7,000	-	4,116	-	-	12,328
Office Expense	17,574	-	715	31,173	-	11,333	-	4,620	65,415
Rent Expense	3,724	-	-	64,775	-	-	-	296	68,795
Repairs and Maintenance	1,307	-	-	-	-	-	-	1,238	2,545
Security	-	-	-	12,249	-	-	-	71	12,320
Postage and Shipping Expense	9,363	-	-	84,031	-	6,889	-	408	100,691
Taxes and Licenses	1,738	325	-	786	-	1,990	-	784	5,623
Telephone Expense	1,827	-	-	4,486	-	1,115	-	316	7,744
Travel Expense	7,460	65	-	133,487	-	7,287	-	11,151	159,450
Utilities	840	-	-	3,975	-	1,139	-	-	5,954
Payroll and Benefits	68,627	-	-	352,979	-	250	-	34,761	456,617
Professional Services	147,240	13,694	-	113,635	-	66,658	9,510	226	350,963
Total General and Administrative Expense	296,637	18,634	3,078	1,465,400	-	110,699	99,881	65,135	2,059,465
Net Ordinary Income	\$ (65,773)	\$ 24,250	\$ 105,073	\$ 49,310	\$ -	\$ (110,699)	\$ 89,625	\$ (35,224)	\$ 56,562
Other Income or Expense	11,516	-	-	-	-	1,505	-	(41)	12,980
Less Net Income from Non Ownership Portion of Subsidiaries	(21,663)	12,125	52,537	9,861	-	-	-	(7,053)	45,807
Net Other Income	33,179	(12,125)	(52,537)	(9,861)	-	1,505	-	7,012	(32,827)
Net Income	\$ (32,594)	\$ 12,124	\$ 52,537	\$ 39,450	\$ -	\$ (109,194)	\$ 89,625	\$ (28,212)	\$ 23,735

MEDICAL MARIJUANA, INC.

Notes to Financial Statements (3-31-14)

Note 1: Summary of Significant Accounting Policies

Nature of Operations.

Medical Marijuana Inc. ("MJNA" or "Company") is an Oregon corporation vested in the medical marijuana and industrial hemp markets. The company is comprised of a diversified portfolio of products, services, technology and businesses solely focused on the cannabis and hemp industries.

These products range from patented and proprietary cannabinoid-based products, to whole plant or isolated high value extracts specifically manufactured and formulated for the pharmaceutical, nutraceutical and cosmeceutical industries.

The Company's services are extensive and varied, ranging from medical clinic management to the capitalization and development of existing industry business and product leaders. Services include development of cannabinoid-based health and wellness products, and the development of medical-grade cannabinoid compounds. Finally, MJNA services include the licensing of its proprietary testing, genetics, labeling, and packaging, tracking, production and standardization methods for the medicinal cannabinoid industry.

Basis of Financial Statement Presentation. The accompanying financial statements have been prepared on the accrual basis. The significant accounting policies followed are described below to enhance the usefulness of the financial statements to the reader.

Cash Equivalents. Holdings of highly liquid investments with maturities of three months or less when purchased are considered to be cash equivalents.

Marketable Securities. Management classifies all investments as available-for-sale. Available-for-sale securities are carried at fair value.

Inventories. Inventories are valued at cost. Inventory consists of CanChew gum and raw materials.

Property, Plant, and Equipment. Property, plant, and equipment are recorded at cost less depreciation and amortization. Depreciation and amortization are primarily accounted for on the straight-line method based on estimated useful lives. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterments and large renewals which extend the life of the asset are capitalized whereas maintenance and repairs and small renewals are expensed as incurred.

Revenue Recognition. Revenue is recognized in the financial statements (and the customer billed) either when materials are shipped from stock or when the vendor bills the Company for the order. Net sales are arrived at by deducting discounts, freight, and sales taxes from gross sales.

Supplementary Information. A breakdown of consolidating income by subsidiary has been included.

Estimates. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Subsidiaries and Corporate Investments

<u>Corporate Holdings</u>	<u>Ownership Percentage</u>
Wellness Managed Services	100%
Canipa Holdings	80%
HempMedsPX	80%
HempWire	50%
Red Dice Holdings	60%
CanChew Biotechnologies	50%
HempVAP™	50%
KannaLife Sciences	16.5%

(See Exhibit A)

Wellness Managed Services

Wellness Managed Services engages in the management, capitalization and development of health and wellness facilities, medical clinics and cooperatives throughout North America.

Wellness Managed Services provides a comprehensive array of clinically-supporting health and wellness products and services that will attract patients while providing for a fully operational, profitable enterprise. We seek to provide facilities and patients alike with the latest in quality products and support services that will serve the health and wellness community. Wellness Managed Services has been actively acquiring and developing its services. This subsidiary is in negotiations for several additional facilities in Canada, California, Colorado and Arizona at present, and is looking to further expand throughout the US as well as develop an international division.

Canipa Holdings

Canipa Holdings was formed to assist Medical Marijuana Inc.'s expansion efforts in Europe, the Middle East and Asia. Canipa Holdings focuses its efforts on obtaining product and marketing approvals as well as distribution partners for the entire line of Medical Marijuana Inc. portfolio of products.

HempMedsPX

HempMedsPX, is a subsidiary of Medical Marijuana Inc. that focuses on the online marketing, distribution and sales of our portfolio of products. Working with various industry companies,

HempMedsPX develops the content and presentations for the various ecommerce sites that promote and sell the products.

Hempwire

Hempwire is a joint venture between HempMedsPX and Livewire, Inc. The venture will concentrate on the distribution of HempMedsPX products.

Red Dice Holdings

Red Dice Holdings, LLC is the owner of the Dixie Brand of products including Dixie Botanicals. The company has over 70 unique consumer products and is one of the most recognizable cannabis and hemp brands in the world. The brands have been featured by *60 Minutes*, *Forbes*, *Fortune*, and *Fast Company*, to name a few.

The company sells direct-to-consumer products, looks to integrate additional brands into its distribution and manufacturing platform, and licenses its brand(s) and IP to others looking to manufacture and distribute the products within their markets. Besides marketing, sales and licensing, the company has a full-time team of researchers and product development specialists who are tasked with improving the products and developing additional delivery methods.

CanChew Biotechnologies

CanChew Biotechnologies focuses on the treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products. The company is focused on the R&D and execution of their clinical development plan for these products and the out-licensing of their technology. Clinical development focuses on the R&D of the formulation, production and the development of chewing gum-based cannabinoid products for the treatment of issues like pain, nausea and vomiting, anorexia, spasticity and various other medical issues.

HempVĀP™

HempVĀP™, a subsidiary of MJNA (50% MJNA and 50% HDDC), is the first hemp-based cannabidiol (CBD) vaporizer product on the market. HempVĀP™ products include flavored CBD-rich hemp oil that is used with a custom-designed HempVĀP™ vaporizer pen. HempVap is sold through HempMedsPX and was launched in the 4th Quarter of 2013.

KannaLife Sciences

KannaLife Sciences (“KannaLife”), is a late-stage biopharmaceutical and phytomedical technology company. They were created to develop natural, phytomedical products to be used in health and wellness regimens. They are also involved in the research and development of novel new therapeutic agents to be used as transport carriers for other compounds seeking to break the blood/brain barrier. They are also developing their own compounds to be used for the treatment and prevention of oxidative and neurotoxic stresses borne from a variety of ailments and illnesses.

Note 2: Related-Party Transactions

Hemp Deposit and Distribution Company

The Company has an agreement with Hemp Deposit and Distribution Company (“HDDC”, d.b.a. CannaBANK Inc.). HDDC is the majority shareholder and acts as the merger, acquisition, and due diligence arm for the Company. HDDC also provides working capital for the Company as needed, or can and has previously provided capital or its equity in MJNA to invest in and purchase companies, products, or services for MJNA.

Note 3: Inventories

Inventories are comprised of hemp-based raw materials and finished goods. Inventory is valued at cost.

Note 4: Investments

The Company maintains a portfolio of equity securities.

Note 5: Receivable RDH

Red Dice Holdings (RDH) is a holding company that owns formulas, equipment, and extraction processes for cannabis-based products. RDH’s revenue model is to continue to develop these products and license them to distributors throughout the world. The Company owns 60% of RDH. The Company has furnished RDH working capital for operations and inventory. As of March 31 2014, it is estimated that RDH owes the Company \$2,977,632. This figure is based upon limited information supplied to the Company by RDH.

The Company has been unable to verify the wholesale sales, cost of goods sold, or any expenses. The actual amount owed to the Company by RDH cannot be determined until independent, audited financial information has been supplied to the Company. Income and Expenses were not included in the Company’s calculation of net income.

As part of the obligation under the RDH joint venture, the Company utilized \$1,450,000 of its securities portfolio as part of its financing strategy to satisfy equity requirements for the transaction. The Company and its management anticipate but have not concluded offsetting a portion, or the entire debt of RDH, by transferring all or a portion of the \$1,450,000 worth of securities in its possession.

Note 6: Red Dice Holdings

The Company purchased Red Dice Holdings in 2012. Red Dice Holdings (RDH) is a holding company, that owns the formulas, equipment, and extraction processes for cannabis-based products. RDH’s revenue model is to continue to develop these products and license them to distributors throughout the world. The Company owns 60% of RDH. RDH also has direct-to-consumer products on the market, such as Dixie Botanicals (a hemp CBD product line that MJNA introduced and paid \$250,000 in fees to launch said product line), and has a Colorado-based licensee that currently has products in over 500 retail outlets.

As part of the obligation under the RDH joint venture, the Company utilized \$1,450,000 of its securities portfolio as part of its financing strategy to satisfy equity requirements for the transaction. The Company and its management anticipate but not have concluded offsetting a portion or the entire debt of RDH by transferring a portion of the \$1,450,000 worth of securities in its possession.

Note 7: CanChew Biotechnologies

The Company purchased CanChew Biotechnologies in 2012. CanChew Biotechnologies focuses on the treatment of pain and other medical disorders with the application of chewing gum based cannabis/cannabinoid medical products. The Company owns 50% of CanChew Biotechnologies. CanChew Biotechnologies has developed an over-the-counter product called CanChew hemp CBD gum, and is also developing its medical product called MedChewRX. The company issued 47,000,000 shares or (\$4,700,000 as of date of issuance) to CanChew Biotechnologies for its use in the clinical development of MedChewRX and the launch of its over-the-counter CanChew gum. To date, none of these shares have been sold or collateralized.

CanChew Biotechnologies' day to day operations are completely controlled and operated by CanChew Biotechnologies' executive management.

Note 8: Research & Development

The Company incurred direct costs for developing their products and intellectual properties.

Note 9: Fixed Assets

Fixed assets are entirely comprised of office equipment. Fixed assets are shown net of depreciation.

Note 10: Stockholders' Equity

At March 31, 2014, the number of authorized and issued shares and the related par value:

Total shares of Common Stock authorized: 5,000,000,000

Total shares of Common Stock currently capped by management: 950,000,000

Total shares of Common Stock outstanding: 949,040,104

Par Value: \$0.001

6. DESCRIBE THE ISSUER'S BUSINESS, PRODUCTS AND SERVICES

A. A description of the issuer's business operations;

1. The Company is in the development stage.
2. To the best of our knowledge the Company is not, nor has ever been, a "shell company."

B. Date and state (or jurisdiction) of incorporation:

The issuer was originally incorporated in Canada as Berkshire Collection. On May 23, 2005, the Company was re-incorporated in the State of Oregon.

C. The issuer's primary and secondary SIC Codes: 7380, Miscellaneous Business Services.

D. The issuer's fiscal year end date: December 31st

E. Principal products or services and their markets:

The Company currently has the following divisions, subsidiaries and affiliates:

Divisions

1. The Hemp Network
2. CannaFuel
3. The Pet Hemp Emporium

Subsidiaries (Companies Owned 50% or more)

1. Wellness Managed Services
2. Ace Hydro
3. HempMedsPX (formerly HempMedsRX)
4. Red Dice Holdings (Dixie Brand)
5. PhytoSPHERE Systems
6. CanChew Biotechnologies
7. Canipa Holdings

Investment Holdings

1. KannaLife Sciences
2. CannaVest Corp.

Affiliates

CannaBANK, Inc. (Hemp Deposit and Distribution Corporation)

Government Regulation

The effect of existing or probable government regulations on the business of the Company is not known at this time. Due to the nature of the business of the Company, it is anticipated that there may be increasing regulation upon the business of the Company and that may cause the company to have to take serious corrective actions, changes in business plan, or even close or stop its business practices and/or operations.

The Company presently has fifty-two (52) team members—including part-time or contracted—within our corporate structure (including subsidiaries).

Prior to new management and the issuance of shares to Hemp Deposit and Distribution, the Company was involved in the following:

(The company's management is continuing its evaluation of the following divisions, strategies, partnerships, business and operational plans for productivity, profitability, marketability and to make sure these fit into the Company's business strategies. The following excerpts were taken directly from prior management's annual reports.)

Medical Marijuana, Inc. was to provide institutional-level financial services to local, state and federal governments, testing and certification services, education programs, as well as consulting and turn-key solutions to all levels of government and the medical marijuana industry. A division, The Hemp Network, established in June 2010, sold hemp-based products to consumers through a network of home-based sales representatives.

EDUCATIONAL SYMPOSIUM AND SEMINARS

The Company began its expanded seminars with its first education forum at the Los Angeles Convention Center on January 16-17, 2010. Shortly thereafter, the Company held its second seminar in April 2010 in San Diego at that city's convention center. The focus of these seminars was on educating entrepreneurs, existing industry operators, regulators, city officials, law enforcement officials and the general public on the benefits of a legitimate medical marijuana industry. Currently no symposium or seminars are planned pending evaluation of the business efficacy of this division.

FINANCIAL SOLUTIONS

Medical Marijuana Inc. had a provisional patent pending for a tax remittance card, which in the early part of 2010 was upgraded and expanded to a utility patent. This would have provided local, state, and federal governments with a closed loop financial accounting system to monitor compliance and collect tax revenues in a near real-time environment. The Company looked to provide an integrated business system for medical marijuana industry participants, from growers to distributors to dispensaries. The Company is putting this product on hold for the time being to focus on other areas of the business.

UNDER NEW MANAGEMENT, FUTURE AREAS OF CONCENTRATION MAY INCLUDE BUT ARE NOT LIMITED TO THE FOLLOWING:

We are currently in discussions with multiple companies for testing, grading and general cannabinoid research.

Co-Op/Collective Management – As the market matures, we intend to provide outsourced management services to dispensaries under contract. We intend to standardize operations and product selection in its group of managed dispensaries.

Hemp Products – We are actively searching for a greatly expandable product line to increase network marketing production.

Medical Marijuana Inc. is currently developing the following divisions and subsidiaries:

1. The Hemp Network.

The Hemp Network's main objective was to educate the general population about the versatility and benefits of the hemp plant. By sharing the story of hemp with individuals across the country and around the world, the network strives to raise awareness and ultimately change public perception about industrial hemp.

Additional Notes: As of this date, the Company has evaluated expenses and overhead to proceed under this option and have elected to run all products through the well-established and nationally-branded HempMedsPX in order to reduce expenditures and maintain consistent control of processes.

2. MMI Nutraceuticals.

MMI Nutraceuticals (MMIN) is a division of the Company that deals with all nutraceutical products including CBD (cannabidiol) and THC-free brands and products. The MMIN team handles the development, research, contracting, patents and sales of these products.

Additional Notes: The CBD nutraceutical product line is expected to generate attention in the United States and abroad because of its purported beneficial properties for humans and animals. Currently we are not aware of any other direct competitors in this marketplace. The Company will look for distributors to sell the future nutraceutical products.

3. MMI Biotechnology

MMI Biotechnology is the division that will build and develop specialty equipment and technology for the medical, herbal, pharmaceutical and nutraceutical markets. The Company has put this focus on hold to concentrate its efforts on product launches and new product acquisitions with existing subsidiaries in the best interest of the Company.

4. CannaFuel

CannaFuel, is a division of the Company that oversees and coordinates the research and development of hemp-based and other biomass-based fuels. Currently the company has put this focus on hold to concentrate its efforts on product launches and new product acquisitions with existing subsidiaries in the best interest of the Company.

5. The Pet Hemp Emporium

Pet Hemp Emporium is a division of the Company that has developed everyday pet products, consisting of everything from hemp leashes to hemp beds and hemp-based bio plastics that are much more suitable for pet use than conventional products that are petroleum (oil)-based. These products are not available to consumers yet. Instead, the Company is anticipating expanding into wholesale distribution and direct distribution to pet stores before investigating marketing these products directly to consumers.

Additional Notes: Currently, the Company can only supply the products in bulk. The Company continues to evaluate the possibility of selling direct to consumer.

Subsidiaries

6. Wellness Managed Services, LLC

Wellness Managed Services provides management support and services to cooperatives, collectives, health and wellness facilities, and medical clinics. The services offered range from management to product distribution.

The Company continues to focus on the viability and structuring of this objective for several reasons:

- a. The accounts will provide, in most cases, an immediate cash flow;
- b. In most cases, the account has shelf space for our products;
- c. In most cases, the accounts provide direct sales access for our products to end-consumers and, most importantly, to the individuals who recommend specific products;
- d. Because the accounts, in most cases, are established businesses, our operating costs are much lower because we aggregate the operating costs in administration, legal, accounting and marketing, giving the company a strategic advantage.

7. HempMedsPX (formerly HempMedsRX) (80% owned by the Company and 20% owned by Hemp Deposit and Distribution Corporation.)

HempMedsPX, LLC is the master distributor and contracted marketing company for the Medical Marijuana Inc. portfolio of hemp-based CBD products. This division is in the process of finalizing exclusive distribution agreements with internal subsidiaries as well as outside parties for a fixed percentage fee plus costs. At the present time, the distribution agreements are with CanChew Biotechnologies for CanChew gum and CannaVest for Real Scientific Hemp Oil (RSHO), Cibdex, and Cibaderm. HempVAP is exclusively marketed and distributed through HempMedsPX. Other entities are being considered for exclusive agreements with HempMedsPX. The name was changed upon advice of our counsel due to our products being plant-based (PX) and not pharmaceutical-based (RX).

The company is in the process of evaluating several potential employees or new hires to run and further develop HempMedsPX. We have hired internal legal and patent consultants, writers, marketing/sales managers, sales staff, distribution staff, a Director of Communications as well as various marketing, website management and product consultants.

8. Red Dice Holdings (60% owned by Medical Marijuana Inc.)

Red Dice Holdings, LLC owns the Dixie Botanical and Dixie Classic brands of consumable products. The Company provides all of the necessary hemp-based CBD oil to Red Dice Holdings brands. The products can be found at retail locations throughout Colorado. Once brand awareness is further established through online presence and media presence, the company anticipates offers from national and international marketing and distribution companies, at which time the company may need to re-evaluate and modify its sales and marketing strategies to conform to a more typical sales and distribution organization.

9. CanChew Biotechnologies

CanChew Biotechnologies focuses on the treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products. The company is focused on the R&D and execution of their clinical development plan and the out-licensing of their technology. Clinical development focuses on the R&D of the formulation, production and the development of chewing gum-based products for the treatment of issues like pain, nausea and vomiting, anorexia, spasticity and various other medical issues.

Product Development

CanChew gum was brought to market first for over-the-counter use. MedChewRX is being developed for medical purposes, specifically pain treatment associated with a variety of long-term, chronic or degenerative diseases whereby cannabinoid therapy is finding increasing application in a global marketplace.

CanChew Advantage

The CanChew formulation offers a unique, socially acceptable, patient-friendly, taste-masked and convenient delivery format for delivery of cannabidiol (CBD) via the oral mucosal membranes.

Advantages of Oral-Mucosal Delivery System for MedChewRX:

- Bypass of the gastrointestinal tract and hepatic portal system, increasing the bioavailability of orally-administered drugs that otherwise undergo hepatic first-pass metabolism.
- Drug is protected from degradation due to pH and digestive enzymes of the middle gastrointestinal tract.
- Improved patient compliance due to the elimination of associated pain with injections.
- Sustained drug delivery.
- A relatively rapid onset of action can be achieved relative to the oral route.
- Oral mucosal systems exhibit a faster initiation and decline of delivery than do transdermal patches.
- The large contact surface of the oral cavity contributes to rapid and extensive drug absorption.

The Company is currently seeking a GMP pharmaceutical manufacturer for its MedChewRX pharmaceutical drug, as well as a partner for clinical development and trials. The two require different GMP certifications. The pharmaceutical drug GMP certification is much more strenuous and is required for MedChewRX's clinical development.

The Company anticipates starting its MedChewRX clinical trials in Europe in 2014, with the overall clinical development taking three to five years. The company has a significant strategic advantage to its product and the development of this business:

1. The company has already developed an over-the-counter product (CanChew), which is available for sale currently. Most companies developing a pharmaceutical drug do not also have a product for sale on the over-the-counter market. This gives CanChew Biotech the ability to fuel its own growth and the growth of its pharmaceutical unit.

2. Gum-based delivery has a much greater efficacy over traditional methods of consuming cannabinoid-based products.
3. The safety profile of MedChewRX's APIs allows for more attractive sponsoring opportunities for research universities and doctors.

10. KannaLife Sciences

KannaLife Sciences ("KannaLife"), is a late-stage biopharmaceutical and phytomedical technology company. They were created to develop natural, phytomedical products to be used in health and wellness regimens. They are also involved in the research and development of novel new therapeutic agents to be used as transport carriers for other compounds seeking to break the blood/brain barrier. They are also developing their own compounds to be used for the treatment and prevention of oxidative and neurotoxic stresses borne from a variety of ailments and illnesses.

KannaLife's unique approach to drug development combines traditional and integrative healthcare practices with modern technology to create a pipeline of potential biopharmaceutical drug candidates for clinical development.

The KannaLife scientific team is comprised of dedicated professionals, clinicians, and biochemists who have a strong background in phytopharmaceutical, biological, and Ayurvedic sciences. This team brings a long track record of successfully developing drugs from plant sources that are complex in nature and structure. The team also has the requisite relationships with nationally-supported institutions of health as well as top academic food and science departments at several recognized universities in the United States.

KannaLife depends on the sustainability of plant life to create its products and practices environmentally-sound business practices. Their ultimate goal is to become a profitable and socially responsible company that seeks to improve the quality of life of the patients needing and using their products.

KannaLife Sciences, Inc.
363 West Hills Road
West Hills, NY 11743
Phone: (516) 669-3219
Fax: (516) 628-8282
URL: <http://www.kannalife.com>

General Inquiries

Email: info@kannalife.com

Public Relations

Email: media@kannalife.com

Medical Marijuana, Inc. is currently working with the following affiliates:

Hemp Deposit and Distribution Corporation (d.b.a. CannaBANK) performs mergers and acquisitions and acts as a conduit through which assets are transferred from Hemp Deposit and Distribution Corporation (“HDDC”) to the Company pursuant to the agreement dated March 23, 2011. CannaBANK is also financing the acquisitions and development of certain approved purchases, acquisitions, and products. CannaBANK is at the forefront of hemp-based investments. Through liquidation of its equity and financial raises, in which CannaBANK guaranteed said funding, CannaBANK provided in excess of \$4 million in financing for the acquisition and development of several pending transactions, including the Dixie Elixirs Brand, PhytoSPHERE Systems, CanChew Biotechnologies, several cannabinoid-based hemp delivery systems, KannaLife Sciences, and several Wellness Managed Services accounts. CannaBANK is expanding its funding resources for the Company.

The nature of products or services offered:

Currently the entire Company’s product and service portfolio is being evaluated by new management for marketability and profitability. The company has investments in other companies and brands which also have products and services.

7. DESCRIBE THE ISSUER'S FACILITIES

As of March 31, 2014, due to the exponential growth the Company has experienced by adding several large vendor accounts, as well as other ventures, the Company has retained additional facilities to provide for said growth. The Company secured three (3) separate executive suites in Poway, CA as well as added a 14,000sf warehouse and distribution center. The Company anticipates adding significantly to personnel to facilitate the expansions. Sales and Customer service will remain at the existing facility.

8. OFFICERS, DIRECTORS AND CONTROL PERSONS

Board of Directors

The Company’s Board of Directors is comprised of highly qualified and industry professionals. The Board assists the Management team in making appropriated decisions and taking effective action. Currently there are two members on the board:

Chairman: Michelle Sides
Director: Michael D. Julian

New Board Member(s)

The Company has and continues to search for qualified individuals that will provide guidance and leadership lending to the success of the business objectives. As such, the Company is proud and honored to have Michael Julian on its board. Mr. Julian has been a highly respected investigator for the State of California and is President/CEO of NBI Professional Investigative Services as well as MPS Security. Mr. Julian will provide assistance not only in business-related matters, but will also lend expertise in locating and vetting future executives, existing partnerships, and future opportunities to ensure that we locate the most qualified individuals and partnerships that are both viable and in line with Company objectives.

Mr. Julian's bio is as follows:

Michael Julian, CPI PPS CSP

Michael grew up working in the PI and security company his father founded in 1967. Beginning in 1990, he started work there full time, specializing in surveillance operations. He obtained his Private Investigators license in 1994 and majored in Administration of Justice in college where he was inducted into the Phi Theta Kappa International Scholastic Order for academic excellence.

After joining the California Association of Licensed Investigators (CALI) in 1995, he served as a District Governor, a member of the Legislation and Technology Committees, Education & Training Task Force, chaired the Bi-Laws Committee, and held the Vice President of Administrative Services position for five terms before becoming president in 2012.

Michael regularly teaches continuing education courses offered by CALI, as well as industry related classes for California State University Fullerton, and National Business Institutes on topics such as business, technology, personal locates, asset discovery, and basic, intermediate, and advanced surveillance techniques.

Michael is a 2003 Executive Protection Institute class 55 graduate and member of the Nine Lives Associates. He has personally provided executive and asset protection to corporate executives, celebrities, natural and man-made disaster victims, and persons-at-risk for over two decades. He also instructs on multiple executive protection topics at EP schools and industry conferences. Michael is one of less than 50 Certified Security Professionals (CSP) in California.

Mr. Julian owns shares of Medical Marijuana Inc.

The Company continues with its efforts to find additional Board Members and Advisor Board Committee Members.

Advisors to the Board

The Company has an informal Advisory Board that is available to provide business advice and counseling to the Management Team of the Company. The Advisory Board is appointed by the President and/or other key executive members, and does not involve itself in any matters involving corporate governance of the Company. There are currently three Advisors to the Board:

Dr. Philip A. Van Damme
Dr. George Anastassov
Lekhram Changoer

Management

Michelle Sides

Chairman of the Board, Chief Operating Officer
4901 Morena Blvd, Suite 701
San Diego, CA 92117

Prior to joining Medical Marijuana Inc., Ms. Sides was Chief Operating Officer for HDDC (d.b.a. CannaBANK), located in San Diego, California. She earned her law degree from Nova Southeastern University. She is a member of the Florida State Bar Association. Ms. Sides holds a Bachelor of Science from Palm Beach Atlantic College, majoring in Business and Organizational Management. Michelle spent six years on the Board of Directors, as Executive Vice President, and as General Counsel for EH Building Group II, LLC, which was nationally recognized as one of the fastest-growing developers in 2006-08, winning numerous awards for production, design, and marketing. Prior to EH, Michelle honed her legal expertise as Legal and Operations Manager for the Commonwealth Network Corporation, as well as the Director of Legal Affairs for Power Sports, Inc. Both of these positions focused mainly on corporate and real estate transactional law.

Ms. Sides is on the Board for Hemp Deposit and Distribution Corporation.
Ms. Sides owns shares of Medical Marijuana, Inc.

Dr. Philip A. Van Damme

Chief Scientific Officer, CanChew Biotechnologies
Kuyperstraat 5
3404 HL Ijsselstein, Netherlands

Dr. Philip A. Van Damme, DMD MD PhD, was born in Yerseke, The Netherlands. Dr. Van Damme is an oral & cranio-maxillofacial surgeon living and working in the Netherlands. Dr. Van Damme first studied dentistry at the Utrecht University Dental School (Rijksuniversiteit Utrecht, The Netherlands) from 1971 through February 1977. He then fulfilled his military duty in the Dutch Royal Navy from May 1977 through October 1978, as Lieutenant-Dentist. Dr. Van Damme studied medicine at the Utrecht University Medical School, the Netherlands from 1978 through January 1983. He trained

in general surgery at the Joannes de Deo Stichting Hospital from July 1983 through April 1984, while taking the International ECFMG/VQE examinations in Paris, France. Dr. Van Damme was trained in Oral & Maxillofacial Surgery in the University Hospital Nijmegen, The Netherlands from May 1984 through May 1988.

His PhD Thesis titled: *Sub periosteal Palatal Soft Tissue Expansion* was submitted on December 6, 1996 at the Nijmegen University (Katholieke Universiteit Nijmegen). Dr. Van Damme has been Section Editor of the Journal of Cranio-Maxillo Facial Surgery, for the sections Research, Development and New Horizons, and Reviewer for different other scientific journals. There are more than 70 PubMed listed publications and he presented more than 100 times at national and international scientific meetings. In 2004, Dr. Van Damme had dual roles of being Visiting Professor in the Mount Sinai Hospital in New York, USA, and Visiting Surgeon in the Burdenko Institute in Moscow, Russia. In subsequent years he held numerous staff positions at several well respected medical clinics in the Netherlands. Together with Prof. George E. Anastassov MD DDS FAC, he has a patent application (US20110097283 – EP2280687 – CA2719830) on chewing gum compositions comprising cannabinoids.

In December 2007, he became Director-owner of Mareda Holding BV (Investment Company) and President-founder of Stichting Sanammad (intellectual property foundation) together with Lekhram Changoer MSc BSc).

Dr. Philip A. Van Damme owns shares of Medical Marijuana Inc.

Dr. George E. Anastassov

Chief Executive Officer, CanChew Biotechnologies
Kuyperstraat 5
3404 HL IJsselstein, Netherlands

Dr. Anastassov graduated with BA Degree in Fine Arts, followed by MD Degree and a DDS Degree, and currently is completing his Executive Physician MBA degree.

Dr. Anastassov is trained in Surgery, Oral and Maxillofacial Surgery, Plastic Surgery and Craniofacial and Base of the Skull Surgery both in the United States and Europe. His training was acquired at the following institutions: A Fellowship in Cranio-Maxillofacial Surgery (Prof. H.P.M. Freihofer), The Catholic University, St. Radboud Hospital, Nijmegen, the Netherlands, Residency at the Department of Oral and Maxillofacial Surgery, Montefiore Medical Centre, Albert Einstein College of Medicine, New York, Followed by a further Fellowship in Craniofacial and Base of Skull Surgery, at the department of Cranio-Maxillofacial and Plastic and Reconstructive Surgery (Prof. Dr. Dhc Ulrich Joos), Wilhelms University, Münster, Germany.

He has variety of clinical and administrative appointments including Associate Clinical Professor Maxillofacial Surgery, The Mount Sinai School of Medicine, Associate Director, Department of Maxillofacial Surgery, Elmhurst Hospital Centre, N.Y.,

Attending, Department of Maxillofacial Surgery, The Mount Sinai Hospital. New York. Consultant in Maxillofacial Surgery, Bronx VA Hospital Centre, N.Y., Attending Surgeon, Department of Otolaryngology/Head and Neck Surgery, Beth Israel Medical Centre, New York. He also is a Visiting Professor, Department of Cranio-Maxillofacial Surgery and Plastic and Reconstructive Surgery, Wilhelm's University, Munster, Germany.

He is the principal at Maxillofacial Surgery Services in New York City.

Editorially, Dr Anastassov is presently active as Editorial Consultant for 'Head and Face Medicine', 'Graefe's Archives for Clinical and Experimental Ophthalmology', 'Journal of Oral and Maxillofacial Surgery', 'The Journal of Oral Surgery, Oral Medicine, Oral Pathology and Radiology', 'Issues in Maxillofacial, Plastic and Reconstructive Surgery, Implantology and Clinical Stomatology' and 'Cranio-maxillofacial Trauma and Reconstruction'. He is on the Editorial Board of 'The International Journal of Oral and Maxillofacial Surgery' and 'Folia Medica'.

Dr. Anastassov holds 9 US & European Professional Society Memberships and is double board certified. Dr. Anastassov has published books and chapters in 3 professional textbooks as well as 46 peer-reviewed journal publications and has presented in as an invited guest lecturer on 104 national and international professional meetings.

Dr. Anastassov owns shares of Medical Marijuana Inc.

Lekhram Changoer

Chief Technology Officer, CanChew Biotechnologies
Kuyperstraat 5
3404 HL IJsselstein, Netherlands

Lekhram Changoer was born in Surinam (South America). Lekhram holds a Bachelor Degree in Analytical/Organic Chemistry and Masters Degree in Organic Chemistry. He has over 20 years of experience in the area of Sales & Marketing, R&D, product development, and quality assurance of technical, consumer healthcare and pharmaceutical products – all servicing European and other international markets.

In 1992, Lekhram first joined IWC Chemical products BV where he was responsible for the development of functional coatings and corrosion inhibitors for the chemical industry: Yara, Kemira, and others. In his second corporate role, Lekhram joined Scott Specialty Gases BV where he was responsible for managing the R&D, QC and QA of functional calibration gases for the petrochemical and automotive Industry for companies such as Mercedes Benz, Rolls Royce, Dera, Shell, Exxon, and General Electric.

In the area of consumer healthcare products, Lekhram worked on the development of cosmetics and medical device products for various retail chains and consumer healthcare companies. At Codi International BV he was responsible for managing product

development in the field of wet wipes and successfully developed products for companies such as Proctor & Gamble, Sara Lee, Henkel and Reckitt Benckiser. In 1999 Lekhram's career took him to Royal Sanders BV with the position of R&D & QC manager – here, he was responsible for the development of cosmetics, medical devices and other healthcare products for clients: Sara Lee, Colgate Palmolive, Virgin Cosmetics, Keune Cosmetics and private labels for various retail chains: Ahold, AC Watson, DM and Rossmann.

In 2002, Lekhram joined the Ardoz/NGen group of companies as a Managing Director. During his tenure his achievements included the filing new patents in the field of active oxygen therapy. This incorporated the accreditation of the products by the Dutch Skin Foundation and the British Dental Health Foundation. He developed new oral healthcare drug applications for periodontitis, peri-implantitis / bone repair and oral mucositis. The OTC products with active oxygen, amongst others also a new chewing gum application (for Perfetti van Melle in Italy), were successfully launched under his directorship in markets at: Boots, Ahold and El Corte Ingles Pharmacy retail and pharmacy chains under the cosmetic 76/768/EEC and medical device 93/42/EEC directive.

In 2010, Lekhram co-founded APeT BV (www.apetholding.com) which focuses on a first of its kind patented therapy for psychiatric diseases like ADHD and Autism as a replacement for methylphenidate and analogs. This therapy involves an in-house developed diagnostic and treatment with the human body's own internal compound(s). The impact on national healthcare has been so important that he has been able to get the largest Dutch insurance company to fund the clinical trial, after which it will most probably become the new standard of care. A new patented pharmacotherapy was filed, which will guarantee protection of the therapy as well as patient therapy loyalty.

In association with Prof. George E. Anastassov MD, DDS, FAC and Dr. Philip A. Van Damme, DMD, MD, PhD, the Sanammad Foundation (www.sanammad.com) was established in 2010 – the Sanammad Foundation holds internationally patent pending technology on chewing gum compositions comprising Cannabinoids.

Lekhram is also involved and co-founder in: CFM Pharma BV (www.cfmpharma.com) which holds patented technologies and focuses on the prevention of secondary injury in indications such as deep burn wounds, myocardial infarct and general trauma. GCP Dental BV (www.gcp-dental.com) has developed a 100% patented biocompatible material for restorative dental applications (where Glass Carbomer® Technology allows the tooth to heal itself) with a global market approach.

Mr. Changoer owns shares of Medical Marijuana Inc.

Tripp Keber

President, Red Dice Holdings

Tripp Keber is President of Left Bank, Inc., a Denver-based real estate investment firm with holdings in Aspen and Denver, Colorado, and Florida. Prior to Left Bank, Mr. Keber held several senior level positions in the telecommunications industry as General Manager of ICG Communications, Senior Vice President for Sales and Marketing at eLink Communications, Sales Director for National Accounts for Pathnet, and as Sales Manager for Winstar Telecommunications. He also served as the Director of Sales and Site Acquisition for Milliwave, LP, and spent three years in sales and sales management in the cable industry. Mr. Keber has a BS in Political Science from Villanova University and currently resides in both Aspen and Denver, CO with his family.

Chuck Smith

Chief Operating Officer, Red Dice Holdings

NOTE: *The Company has and continues to retain various legal, financial and administrative professionals to assist with operations until the right individuals can be vetted and brought on with the Company. We are actively seeking experienced qualified professionals for executive positions as well as Board vacancies. Any interested party may submit their resume to the attention of Michelle Sides at HR@MedicalMarijuanaInc.com*

B. Legal/Disciplinary History.

None of the above named persons have been the subject of:

- A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding within the past five years
- The entry of an order, judgment or decree not subsequently reversed, suspended or vacated by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended, securities, commodities, or banking activities.
- A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended or vacated or,
- The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

C. *Beneficial Shareholders of 5% or more.*

Name	Address	Shares or Controlled	%
Hemp Deposit and Distribution Corp. And its affiliates: CanChew CannaBANK Red Dice Holdings Management Investors	2665 Ariane Drive, #207 San Diego, CA 92117	341,654,437 Restricted/Affiliated	36

9. THIRD PARTY PROVIDERS.

Security and Exchange Counsel

Law Offices of Michael Corrigan
Michael Corrigan, Esq.
Carmel Valley Centre II
11995 El Camino Real, Suite 301
San Diego, CA, 92130

FDA Counsel

Duane Morris LLP
Michael Swit, Esq.
750 B. Street, Suite 2900
San Diego, CA 92101

Auditor

Anthony W. Imbimbo
Anthony W. Imbimbo & Associates
2445 5th Avenue, Suite 350
San Diego, CA 92101

Investor Relations Consultant

Stuart Smith
SmallCapVoice.Com, Inc. - Stuart Smith
(512) 267-2430
ssmith@smallcapvoice.com
www.smallcapvoice.com

Internal - Investor Relations Contact

Perry Coleman
Phone: (443) 453-5088
perry@medicalmarijuanainc.com

UPDATES: (Subsequent Events and Updates are Italicized after the appropriate section to provide the most current information as of the date of this posting.)

Depository Trust Company ("DTC") Chill - The Company is proud to announce that after full compliance with all requested information, the DTC notified the Company that it lifted the chill as of August 21, 2013.

2-Year Audit Status - As of March 31, 2014, the auditor has completed 20 of 24 months of audits. In the meantime, we are actively seeking an SEC auditing firm that will review all audited financials upon completion to move forward as part of the uplisting requirements. This option was the chosen course of action to save significant cost to the Company to have all quarters audited and then submitted together to an SEC firm to finalize.

Due to the inability to audit information provided by former management upon acquisition and transition of MJNA, the Company has elected to base the uplisting requirements strictly on audited financials which has caused a delay in the initial date estimate but the decision was made in the best interest of the Company.

Office Move - As of March 31, 2014, due to the exponential growth the Company has experienced by adding significant vendor accounts, as well as other ventures, the Company has retained additional facilities to provide for said growth. The Company secured three (3) separate executive suites in Poway, CA as well as added a 14,000sf warehouse and distribution center. The Company anticipates adding significantly to personnel to facilitate the expansions. Sales and Customer service will remain at the existing facility. The Company will commence hiring in May to staff this growth.

Security Exchange Commission (SEC) Inquiry - As with many in this progressive industry and emerging market, on June 17, 2013, we received a letter from the Staff of the Division of Enforcement of the SEC informing the Company that it is conducting an *informal inquiry (NOT an investigation)* and requesting that the Company provide certain documents and information relating to current and former management of the Company, communications between the Company and governmental agencies, operations of the Company, and other matters referenced in the letter. ***The letter advised that the informal inquiry should not be construed as an indication by the SEC or its staff that any violations of law have occurred, or as an adverse reflection upon any person or security.***

The Company has fully cooperated with the SEC with requested information. To further show full disclosure, the Company has voluntarily elected to continue to provide information on a rolling basis and will continue to do so upon any request.

The Red Dice Holdings, LLC (RDH) Matter

MJNA and Dixie Holdings LLC, a/k/a Dixie Elixirs (“Dixie”) are the sole members of a limited liability company formed in 2012 known as Red Dice Holdings, LLC (“RDH”). RDH was formed for the purpose of engaging in the manufacture and distribution of legal hemp and cannabis-based products. A dispute has arisen between MJNA and Dixie pertaining to the management, operations and capitalization of RDH. Dixie operates RDH’s business activities on a day-to-day basis and MJNA has demanded a proper accounting from Dixie on numerous occasions, to no avail. On July 12, 2013, MJNA issued termination letters for the existing management of RDH based upon failure to comply with the RDH Operating Agreement and several claims of mismanagement. While MJNA and Dixie were engaged in discussions relative to a possible mediation of the dispute, on July 18, 2013, Dixie filed a lawsuit against MJNA in Superior Court for the State of California, County of San Diego, alleging (1) breach of contract; (2) specific performance; and (3) declaratory relief. Each cause of action is expressly based upon an allegation that MJNA is in breach of RDH’s Operating Agreement by failing to contribute shares of common stock of MJNA to RDH for capitalization purposes. As Dixie has been advised, MJNA intends to assert several affirmative claims against Dixie for money damages and other provisional relief. However, because RDH’s Operating Agreement states that all disputes “between Members arising out of this Agreement” must be arbitrated, in compliance with the Operating Agreement, MJNA filed a petition to compel transfer of the matter to private arbitration (rather than a court proceeding). On November 15, 2013, The Honorable Richard E.L. Strauss, judge presiding, granted MJNA’s petition to compel arbitration. While the parties have engaged in settlement discussions and are attempting to resolve the dispute, the matter is currently pending. If the matter proceeds through arbitration, MJNA intends to vigorously defend Dixie’s claims while vigorously prosecuting its affirmative claims against Dixie.

UPDATE:

As of April 29, 2014, the Company has entered into a finalized amicable resolutions with Dixie Holdings and its management. MJNA now owns 100% of Red Dice Holdings, LLC. The terms of the agreement provide that Dixie Holdings will retain ownership of Dixie Elixirs and Edibles allowing it to continue to expand its THC-infused products. Dixie Botanicals brand and IP will be owned 100% by MJNA that is specifically dedicated to CBD-infused products. Although, this may be deemed confusing to some consumers, due to the significant resources that MJNA has contributed building this brand, at this time, the Company will continue with this line of products until further determination is made on expansion and/or consolidation as well as a full audit of operations to reduce operational cost and expand market potential. MJNA will continue to educate the public on our CBD based products. This resolution allows both parties to place 100% of its focus on its own company business objectives in the respective markets.

HEMPMEDSPX QUARTERLY REVIEW:

HempWire, LLC

On April 8, 2014, The Company entered into a joint venture with LiveWire Ergogenics Inc (OTCQB: LVVV) and collectively formed HempWire, LLC. The initial success of this venture resulted in a \$1.1 million dollar purchase order which sets into motion production of retail packaged cannabidiol (CBD) rich hemp oil infused energy chew squares. The Company received 2m shares of LVVV as consideration for entering into joint venture and the Company has guaranteed HempWire fixed cost on CBD rich hemp oil for future products. HempWire's distribution network includes LiveWire's extensive chain of existing convenience store retailers, grocery stores, and pharmacy chain stores in addition to the established sales network of Medical Marijuana Inc.'s HempMedsPX™.

Through HempMedsPX™, Medical Marijuana Inc. significantly increased its cannabidiol (CBD)-rich hemp oil awareness campaign in the first quarter of 2014. Operational highlights from Q1 include the following:

HempMedsPX™ was the first CBD-rich hemp oil company to be accepted by the American Herbal Products Association (AHPA) for membership. The AHPA is the only national trade association that is focused primarily on herbs and botanicals and herbal products. In addition to AHPA membership, HempMedsPX™ is a sponsor of the AHPA's 2014 events.

HempMedsPX™ supported the American Academy of Anti-Aging Medicine (A4M) as a Platinum Elite Sponsor, expanding brand awareness to the organization's membership base of more than 26,000 medical and healthcare professionals.

HempMedsPX™ signed a two-year supplier agreement with a home-based business. The first purchase order from this business totaled \$1,072,251 in products.

HempMedsPX™ sponsored and participated in the 5th Annual U-T Successful Living Expo, a San Diego event focused on the unique health and wellness concerns of the 55-and-older demographic. In support of this event, information about CBD from hemp was also shared with more than 350,000 San Diego Union-Tribune (U-T) Sunday newspaper subscribers and 70,000 U-T email subscribers through print and online advertising. HempMedsPX™ presented "What's the Buzz About CBD?" during the expo, informing attendees about an alternative to medical marijuana.

The Company was the only hemp CBD exhibitor at the *HIGH TIMES* Los Angeles Medical Cannabis Cup and received an overwhelmingly positive reception by attendees February 8-9.

On March 20th, Medical Marijuana Inc. announced that the Company signed a memorandum of understanding (MOU) to develop a joint venture with LiveWire Ergogenics, Inc. under the name of HempWire, LLC. The CBD-rich hemp oil used in these HempWire products is sourced from HempMedsPX™.

Medical Marijuana Inc. announced on March 31st that due to the exponential growth of its subsidiary company, HempMedsPX™, the Company is moving to a larger multi-building campus location in the Scripps Poway Parkway area of San Diego. The current location will serve as administrative offices for other Medical Marijuana, Inc. subsidiaries.

Media exposure expanded significantly in the first quarter. Media coverage included:

Natural Awakenings: “A New Super Hemp Oil?”

NBC 7 San Diego: Feature story by Candice Nguyen – “San Diego Company Sells Legal Alternative to Medical Marijuana.”

The Voice of Merrill: Conservative talk radio show invites Medical Marijuana Inc. on the air.

Leaf Science: Interview with Charles Vest, HempMedsPX™ VP of Communications.

FOX 5 News San Diego: Featured HempMedsPX™ products in their news segment entitled, “Healing with Hemp.”

WHAS-TV 11 Kentucky: Use of CBD-rich hemp oil was featured on news segment. The story included comments from Deb McGrath of the Epilepsy Foundation of Kentuckiana and Kentucky State Senator Julie Denton.

Fox News Tampa Bay: Renee Petro from Florida defends her use of Real Scientific Hemp Oil™ (RSHO™) for her son.

Trade shows and expos featuring products from HempMedsPX™ included:

- January 9-13: International Gift & Home Furnishings Marketplace – Atlanta, GA
- January 21-23: CHAMPS – Las Vegas
- January 25-27: ISSE International Salon & Spa Expo – Long Beach, CA
- January 29-30: Tobacco Plus Expo – Las Vegas
- February 1: U-T Successful Living Expo – San Diego, CA
- February 8-9: HIGH TIMES Medical Cannabis Cup, Los Angeles
- March 6: AHPA Member Breakfast & Herbwalk
- March 7-9: Natural Products Expo West – Los Angeles
- March 13-16: A4M BHRT Symposium / Fellowship – San Francisco
- March 16-19: ASD – Las Vegas

Continuing the Company's community outreach efforts, support was given to MyCompassion.org and efforts to create awareness of CBD-rich hemp oil products expanded throughout the Midwest in March. HempMedsPX™ contributed to the efforts of AutismOne in support for the organization's global annual conference. The co-Founder of AutismOne promoted HempMedsPX™ through their radio broadcast on VoiceAmerica in the first quarter. Charles Vest, VP of Communications for HempMedsPX™, issued a call-to-action for charitable organizations that would like HempMedsPX™ support to contact community@hempmedspx.com for details.

Medical Marijuana Inc.'s subsidiary Wellness Managed Services launched a joint venture with MPS Security under the brand MPS International (MPSI) on January 1, 2014. Operational highlights from Q1 include the following:

MPSI's focus on expanding operations included:

- Hired 3 reps- 2 in Colorado and 1 in Washington
- Finalized leases for a building location in Denver for a service that will be announced in May
- Purchased 2 armored trucks for the Denver location

CBD-rich hemp oil products sold in the Denver market are approximately \$45,000

Expanded service offerings to include "consultative services"

Landed the security account for the Denver Mart – annual revenue expectation \$250,000

Began providing security in four dispensaries and retail marijuana stores

Additional Departments Created and New Hires - As the Company grows, we will continue to add appropriate personnel to better market, sell, and distribute our products. In 2013, the following departments were created:

Sales and Customer Service – The staff for this department are comprised of trained sales professionals to implement sales strategies, follow-up calls, and customer/general public inquiries. The Sales and Customer Service teams are supervised by the Director of Sales.

Marketing – In addition to hiring a VP of Communications to oversee all marketing and outreach initiatives, the new marketing staff currently includes graphic designers, copywriters, web developers, and other marketing professionals.

Social Media – This department is developing a complete social media presence for the Company and its subsidiaries. These team members report to the Director of Sales and the Director of Communications.

As more team members and departments are added, we will update shareholders and the general public via email and/or social media communications.

11. ISSUER CERTIFICATION.

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other person with different titles, but having same responsibility).

The certification shall follow the format below.

I, Michelle L. Sides, Chairman and Chief Operating Officer, certify that:

1. I have reviewed this quarterly statement of Medical Marijuana Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, which have been prepared by the Company auditor, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: June 27, 2014

Chairman and COO Signature:

A handwritten signature in black ink, appearing to read "Michelle L. Sides", written over a horizontal line.